Table 3.
Univariate and multivariate analysis of prognostic factors in HCC (cohort 2, n=128)
| Variables | TTR
|
OS
|
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Univariate analysis | ||||
| Gender, male vs female | 1.59 (0.58–4.37) | 0.364 | 3.08 (0.71–13.8) | 0.133 |
| Age, years, ≥50 vs <50 | 1.82 (0.80–4.16) | 0.155 | 1.76 (0.69–4.49) | 0.238 |
| HBsAg, positive vs negative | 1.41 (0.32–6.19) | 0.652 | 2.42 (0.65–9.02) | 0.186 |
| GGT, U/L, ≥50 vs <50 | 1.03 (0.50–2.13) | 0.935 | 1.42 (0.69–2.89) | 0.342 |
| AFP, ng/mL, ≥400 vs <400 | 1.74 (0.87–3.45) | 0.116 | 1.79 (0.77–4.16) | 0.176 |
| Cirrhosis, yes vs no | 1.11 (0.48–2.53) | 0.812 | 1.37 (0.55–3.41) | 0.500 |
| Tumor size, cm, ≥5 vs <5 | 1.55 (0.83–2.90) | 0.168 | 1.95 (0.95–4.03) | 0.040 |
| Tumor number, multiple vs single | 1.37 (0.57–3.29) | 0.476 | 1.10 (0.45–2.73) | 0.833 |
| MVI, yes vs no | 4.95 (2.23–11.01) | 0.000 | 4.46 (1.69–11.78) | 0.003 |
| Tumor encapsulation, none vs complete | 1.12 (0.59–2.16) | 0.726 | 1.14 (0.56–2.35) | 0.718 |
| Tumor differentiation, III-IV vs I–II | 1.02 (0.54–1.93) | 0.958 | 1.60 (0.82–3.14) | 0.171 |
| TNM stage, II+III vs I | 2.06 (0.91–4.67) | 0.085 | 2.10 (0.88–5.02) | 0.095 |
| Serum miR-125, high vs low | 0.51 (0.25–1.05) | 0.067 | 0.61 (0.29–1.26) | 0.178 |
| Exosomal miR-125, high vs low | 0.14 (0.06–0.33) | 0.000 | 0.35 (0.16–0.77) | 0.009 |
| Multivariate analysis | ||||
| Tumor size, cm, ≥5 vs <5 | 1.97 (1.02–3.81) | 0.025 | ||
| MVI, yes vs no | 3.82 (2.02–7.20) | 0.000 | 4.76 (2.13–10.61) | 0.000 |
| Exosomal miR-125b, high vs low | 0.14 (0.07–0.29) | 0.000 | 0.36 (0.18–0.74) | 0.005 |
Notes: Cox proportional hazards regression model. The bold values indicate P-value <0.05.
Abbreviations: AFP, alpha-fetoprotein; GGT, gamma-glutamyl transferase; HCC, hepatocellular carcinoma; MVI, microvascular invasion; OS, overall survival; TNM, tumor-node-metastasis; TTR, time to recurrence.